From Main Street To Wall Street And Back: Cal-X Determined To Help Startups Succeed

Investment crowdfunding isn’t an idea born on Capitol Hill. It is an idea forged in the minds of entrepreneurs, a child of their own difficulties accessing capital.

California-Stock-Exchange

As Howard J. Leonhardt sat in the White House Rose Garden watching President Obama sign the JOBS Act into law on April 5, 2012, he was overwhelmed with a feeling of relief that future entrepreneurs may not be faced with the difficulties and the frustrations he faced in building his first company.

“I had chills up my spine,” he said. “I really believe in the depth of my heart that that signature was just as important as when President Lincoln was signing the freeing of the slaves. To me it’s that impactful, that important, and I really believe that most of the population of the US is underestimating the importance of the JOBS Act and particularly the crowdfunding provision.”

One can’t understand why Leonhardt would say such a profound thing without first understanding his back story. Beginning as a young entrepreneur, his story would eventually result in numerous medical breakthroughs and a series of new companies. It is also pockmarked with the all-too-familiar tales of regulatory hurdles, high costs and time wasted.

His frustrations would lead him to lobby for passage of the JOBS Act. He’d later launch a venture fund, two accelerators and a stock exchange, eventually funding 28 companies and counting.

In a way his story is the story of why the JOBS Act came to be in the first place, mirroring the experiences of Woodie Neiss, Jason Best and the other entrepreneurs that saw a need for radical change in the rules governing access to capital in the United States.

Friends And Family

What does a young mind with a great idea do when that idea would cost millions to bring to market?

Leonhardt was faced with this question after attending the University of Florida. He founded his first company, World Medical Corp., in 1986. The goal: to bring revolutionary new biotech products to market, specifically products for treating cardiovascular conditions. The process of fundraising began.

This is the first time he was faced with the regulatory realities of raising capital in the United States. He needed access to millionaires, but his upbringing in a largely blue collar neighborhood meant he didn’t know any. The average income of the households in his neighborhood was around $40,000. He would learn that regulations prevented him from soliciting investment from anyone he didn’t already know.

After pitching his friends and family, Leonhardt had 35 investments of a thousand dollars each, no doubt a humbling vote of confidence from people without a lot of expendable cash in the coffers. Thanks to this new round of non-accredited investments in his company, legal fees doubled from $10,000 to $20,000, effectively skimming almost 30% of the money he had just raised from those closest to him; The money that he had promised would be put to good use.

Feeling angry and betrayed by the system, he dreamed of going to Washington one day to fix things, but it would have to wait. He had a company to build.

Lives Saved, Lives Lost

Things were going well and eventually Leonhardt realized that he needed a factory, but before he could get the factory he would need a million dollars to acquire it. It would take years to get the money he needed to expand.

“We ended up finding a way to do it which is almost impossible,” he said. “We wholesaled other products and we private labeled products and we earned the money to get the million to build the factory. We couldn’t get capital from outsiders. It took ten years longer than it would have taken otherwise, and finally when we broke loose we went from 35 employees to 550 employees and saved 200,000 lives. All of that was delayed.”

“In a certain way, I think the SEC holds – as they do again and again – blood on their hands that developments that could have saved millions of lives are held up because the rules are so daunting that you can’t get the capital to do it.”

A manufacturing-focused spinoff of his original company, World Medical Manufacturing Company would eventually bring over 15 cardiovascular products to market including cardiovascular balloon catheters, percutaneous heart valves, intravascular lung catheter and the world’s leading aortic stent graft system – the TALENT (Taheri-Leonhardt) stent graft.

Those 15 products were delayed years while Leonhardt tried to find ways to raise money. They would later be credited with saving as many as 200,000 lives. Death rates for associated cardiovascular diseases would be reduced from 90% to less than 1%.

War

HowardLeonhardtBioHeart1Eventually Leonhardt would shift focus to Bioheart Inc. Bioheart aimed to take World Medical Manufacturing’s progress a step further. A modified stent would be used as the delivery mechanism for Bioheart’s breakthrough treatment, a treatment that would use stem cells to help heal scar tissue of the heart.

Leonhardt knew Medicare was spending $8 billion on heart failure drugs every year, and the drugs that did dominate the market left a lot to be desired. Quality of life for patients was generally poor.

After years of research Bioheart’s method was ready for trials. Clinical trials would cost $7 million. The year was 2008 and the US economy was in a tailspin. Bioheart would go on to be the only biotech IPO in the United States that year, raising $6.5 million.

Trials have shown cause for optimism. A one-half hour injection session of myoblast cells using technology from Bioheart Inc. delivers great results in a majority patients, and results tend to improve with subsequent injections. It could one day revolutionize how we treat heart failure in the United States and around the world.

After the 2008 IPO, Leonhardt asked to see the tabulation of cost for the IPO. The total?

$4.8 million, more than half of the $6.5 million raise.

“Heart failure is the the leading drain on Medicare in the United States, and we have the solution and we can’t get it to market because the capital raising system is broken. I was furious. I resigned as CEO, and I went up to Washington and started yelling at people.”

The California Accelerator, Cal-X Stars & The California Stock Exchange

Today, Leonhardt is putting his experience to good use, traveling and evangelizing crowdfunding in his home state of California and beyond. He is planning a run for Lt. Governor of the State of California (a post with a heavy focus on economic development), and he is the state spokesperson for the JOBS Act and crowdfunding in California, a position he was asked to fill by Startup America Partnership.

He also launched Leonhardt Ventures, a venture fund that has invested over $145 million in 28 companies to date.

A logical extension of this venture fund was a small business accelerator. In 2008 Cal-X was launched. Cal-X’s top product at the moment is called “Cal-X Crowdfunding Connect,” which specializes in California Qualification by Permit offerings. These deals are available to residents and businesses of California. Investors must be accredited as defined by California securities law, so Cal-X is participating in equity crowdfunding right now as we wait for rules to come from the SEC.

Cal-X also offers two accelerators: the California Accelerator, which is a 12 week accelerator. There is also a comprehensive, napkin-concept-to-IPO 5 year accelerator called Cal-X Stars. All of this is centered around a new California Stock Exchange, or Cal-X, which Leonhardt says is ”designed to be the very first concious capitalism stock exchange with an emphasis on local investing.”

Cal-X Stars is the only 5 year business accelerator that is partnered with Cal-X The California Stock Exchange registering with the SEC with intent to serve as the leading U.S. exchange focused on serving smaller firms. Cal-X Stars selects the best startups to be engaged in a full co-founder partnership with the goal to first get listed on Cal-X and later on NASDAQ or NYSE.

Leonhardt says the choice to place all of these under a California brand was deliberate. ”We wanted to go with that name because we think we embody the spirit of California, the entrepreneurial spirit, the little bit of slant to the left as far as caring for the community and the environment,” he said. “We’re going to try to create a feel good marketplace where people that never thought of investing are all of the sudden going to want to participate.”

The exchange aims to break the walls down between CEO and investor. Leonhardt wants to place emphasis on the human aspect of businesses, the people that create them and the passion they have for their ideas.

“When our investors sign on to the California Stock Exchange in the future, the number one thing they’ll be directed to is a local investing meeting that is taking place in their city where we’ll showcase entrepreneurs raising cpaital in their community… we want the investors to meet in person the CEO and the CFO of the company and develop trust and rapport, which is very different from the Wall Street way.”

Cal-X is seeking a technology partner in an effort to license secure, effective trading software. They are also in the process of acquiring a space in San Francisco or LA.

Wherever the market ends up, I wouldn’t bet on a Wall Street mailing address.